Strong growth and capital returns face healthcare inflation and commercial pricing pressure.
| Quarter | Q2 FY23 |
|---|---|
| Length | 14 minutes |
| EPS | $0.83 |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q3 FY26 · Q2 FY26 · Q1 FY23
All CRVL earnings · Back to CRVL overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.